Research analysts at StockNews.com began coverage on shares of Affimed (NASDAQ:AFMD – Get Free Report) in a report issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Several other research firms also recently commented on AFMD. Berenberg Bank reissued a “buy” rating and issued a $6.00 price objective on shares of Affimed in a research note on Tuesday, August 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 price target on shares of Affimed in a research report on Monday, September 25th. Truist Financial lowered their price target on Affimed from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Friday, August 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Affimed in a research note on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Affimed currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.
Affimed Stock Performance
Affimed (NASDAQ:AFMD – Get Free Report) last announced its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, meeting the consensus estimate of ($0.22). The company had revenue of $1.51 million during the quarter, compared to analysts’ expectations of $4.83 million. Affimed had a negative return on equity of 79.96% and a negative net margin of 357.49%. Equities research analysts predict that Affimed will post -0.84 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Affimed
Hedge funds and other institutional investors have recently made changes to their positions in the business. Y Intercept Hong Kong Ltd acquired a new stake in shares of Affimed in the second quarter worth $129,000. Goldman Sachs Group Inc. lifted its position in shares of Affimed by 18.6% in the 2nd quarter. Goldman Sachs Group Inc. now owns 307,729 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 48,178 shares during the last quarter. Ergoteles LLC acquired a new position in Affimed during the 2nd quarter valued at approximately $85,000. Two Sigma Securities LLC bought a new position in shares of Affimed during the second quarter worth about $45,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Affimed in the 2nd quarter worth about $31,000. Hedge funds and other institutional investors own 30.82% of the company’s stock.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.
- Five stocks we like better than Affimed
- Comparing and Trading High PE Ratio Stocks
- MarketBeat Week in Review – 11/6 – 11/10
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Data giants MongoDB and Snowflake just got upgraded
- Technology Stocks Explained: Here’s What to Know About Tech
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.